Tom

About Tom Rauscher

This author has not yet filled in any details.
So far Tom Rauscher has created 4 blog entries.

Two Labs Joins GS1 Healthcare US Initiative

2020-03-13T12:36:34+00:00March 13th, 2020|Categories: Blog|

Two Labs Joins GS1 Healthcare US Initiative Two Labs is a new member of the GS1 Healthcare US Initiative and will be joining the Rx Supply Chain Security Workgroup (RxSSC) in 2020.The GS1 Healthcare US Initiative includes over 140 healthcare manufacturers, distributors, providers, dispenser pharmacies, group purchasing organizations, government agencies and industry associations who are working together to help address challenges where GS1 Standards can have an impact. [...]

Pricing and Market Access Considerations for Cell and Gene

2020-03-04T22:43:35+00:00February 27th, 2020|Categories: Blog|Tags: , , , |

Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]

What is Compendia’s Impact on Product Decision Making?

2020-03-04T13:52:02+00:00February 26th, 2020|Categories: Blog|Tags: , , |

What is Compendia’s Impact on Product Decision Making? What is “The Compendia”? Most often, people describe the organizations that make up the Compendia as price books – and that’s understandable. After all, most of the submissions a manufacturer makes to Compendia involves price increases throughout the product launch year until they maintain price on a regular basis. And yes, pricing is absolutely a key part of what they do, however, [...]

An Overview of Cell and Gene Therapies

2020-03-04T13:53:10+00:00February 24th, 2020|Categories: Blog|Tags: , , , |

An Overview of Cell and Gene Therapies Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration. Gene Therapy Launch Timeline Gene Therapy Product Overview Product Indication Therapy Type Price Kymriah Childhood B-cell acute lymphoblastic leukemia (ALL) Diffuse large B-cell lymphoma (DLBCL) CAR-T [...]

Contact Info

110 Riverbend Avenue, Suite 100, Powell, OH 43065

Phone: 614.389.4004

Fax: 866.259.4324

Recent News